nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—skin cancer	0.494	1	CbGaD
Lenalidomide—ABCB1—Vismodegib—skin cancer	0.0448	0.557	CbGbCtD
Lenalidomide—ABCB1—Dactinomycin—skin cancer	0.0235	0.292	CbGbCtD
Lenalidomide—TNFSF11—leg—skin cancer	0.0206	0.137	CbGeAlD
Lenalidomide—TNFSF11—forelimb—skin cancer	0.0204	0.136	CbGeAlD
Lenalidomide—TNFSF11—hindlimb—skin cancer	0.0184	0.122	CbGeAlD
Lenalidomide—TNFSF11—appendage—skin cancer	0.0157	0.105	CbGeAlD
Lenalidomide—ABCB1—Docetaxel—skin cancer	0.0122	0.151	CbGbCtD
Lenalidomide—CDH5—endothelium—skin cancer	0.00715	0.0477	CbGeAlD
Lenalidomide—CDH5—blood vessel—skin cancer	0.00659	0.044	CbGeAlD
Lenalidomide—CDH5—nipple—skin cancer	0.00477	0.0318	CbGeAlD
Lenalidomide—TNFSF11—connective tissue—skin cancer	0.00449	0.03	CbGeAlD
Lenalidomide—CDH5—connective tissue—skin cancer	0.00338	0.0225	CbGeAlD
Lenalidomide—TNFSF11—lymphoid tissue—skin cancer	0.00329	0.0219	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—MITF—skin cancer	0.00324	0.16	CbGpPWpGaD
Lenalidomide—CDH5—epithelium—skin cancer	0.00321	0.0214	CbGeAlD
Lenalidomide—CRBN—nipple—skin cancer	0.00303	0.0202	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—SHH—skin cancer	0.00285	0.141	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—MITF—skin cancer	0.00285	0.141	CbGpPWpGaD
Lenalidomide—CDH5—mammalian vulva—skin cancer	0.00278	0.0186	CbGeAlD
Lenalidomide—PTGS2—leg—skin cancer	0.00267	0.0178	CbGeAlD
Lenalidomide—TNFSF11—head—skin cancer	0.00265	0.0177	CbGeAlD
Lenalidomide—CDH5—lymphoid tissue—skin cancer	0.00247	0.0165	CbGeAlD
Lenalidomide—PTGS2—hindlimb—skin cancer	0.00239	0.0159	CbGeAlD
Lenalidomide—CDH5—female reproductive system—skin cancer	0.00238	0.0159	CbGeAlD
Lenalidomide—Pomalidomide—PTGS2—skin cancer	0.00221	0.608	CrCbGaD
Lenalidomide—PTGS2—appendage—skin cancer	0.00205	0.0137	CbGeAlD
Lenalidomide—CDH5—head—skin cancer	0.00199	0.0133	CbGeAlD
Lenalidomide—TNFSF11—lymph node—skin cancer	0.00185	0.0124	CbGeAlD
Lenalidomide—CRBN—mammalian vulva—skin cancer	0.00177	0.0118	CbGeAlD
Lenalidomide—PTGS2—skin epidermis—skin cancer	0.0017	0.0114	CbGeAlD
Lenalidomide—CRBN—lymphoid tissue—skin cancer	0.00157	0.0105	CbGeAlD
Lenalidomide—CRBN—female reproductive system—skin cancer	0.00151	0.0101	CbGeAlD
Lenalidomide—Thalidomide—PTGS2—skin cancer	0.00142	0.392	CrCbGaD
Lenalidomide—CDH5—lymph node—skin cancer	0.0014	0.0093	CbGeAlD
Lenalidomide—CRBN—head—skin cancer	0.00127	0.00844	CbGeAlD
Lenalidomide—PTGS2—endothelium—skin cancer	0.00124	0.00825	CbGeAlD
Lenalidomide—PTGS2—blood vessel—skin cancer	0.00114	0.0076	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—RASA1—skin cancer	0.00113	0.0558	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—RASA1—skin cancer	0.00107	0.0527	CbGpPWpGaD
Lenalidomide—CRBN—lymph node—skin cancer	0.000886	0.00591	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—skin cancer	0.000706	0.0348	CbGpPWpGaD
Lenalidomide—ABCB1—blood vessel—skin cancer	0.000706	0.0047	CbGeAlD
Lenalidomide—PTGS2—connective tissue—skin cancer	0.000585	0.0039	CbGeAlD
Lenalidomide—PTGS2—epithelium—skin cancer	0.000555	0.0037	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IL6—skin cancer	0.000551	0.0272	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—IL6—skin cancer	0.000542	0.0267	CbGpPWpGaD
Lenalidomide—PTGS2—skin of body—skin cancer	0.000528	0.00352	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—RHOU—skin cancer	0.000443	0.0218	CbGpPWpGaD
Lenalidomide—PTGS2—lymphoid tissue—skin cancer	0.000428	0.00285	CbGeAlD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—MITF—skin cancer	0.000419	0.0207	CbGpPWpGaD
Lenalidomide—PTGS2—female reproductive system—skin cancer	0.000412	0.00275	CbGeAlD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.000392	0.0193	CbGpPWpGaD
Lenalidomide—PTGS2—head—skin cancer	0.000345	0.0023	CbGeAlD
Lenalidomide—ABCB1—epithelium—skin cancer	0.000343	0.00229	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NRAS—skin cancer	0.000309	0.0152	CbGpPWpGaD
Lenalidomide—ABCB1—mammalian vulva—skin cancer	0.000298	0.00199	CbGeAlD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.000293	0.0144	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—NRAS—skin cancer	0.000291	0.0144	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	0.000266	0.0131	CbGpPWpGaD
Lenalidomide—ABCB1—lymphoid tissue—skin cancer	0.000265	0.00176	CbGeAlD
Lenalidomide—ABCB1—female reproductive system—skin cancer	0.000255	0.0017	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—KRAS—skin cancer	0.000251	0.0124	CbGpPWpGaD
Lenalidomide—PTGS2—lymph node—skin cancer	0.000241	0.00161	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	0.000226	0.0111	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTCH2—skin cancer	0.000216	0.0107	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6—skin cancer	0.000216	0.0107	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—HRAS—skin cancer	0.000213	0.0105	CbGpPWpGaD
Lenalidomide—ABCB1—head—skin cancer	0.000213	0.00142	CbGeAlD
Lenalidomide—PTGS2—Spinal Cord Injury—CSPG4—skin cancer	0.000209	0.0103	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—IL6—skin cancer	0.000204	0.0101	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GLI2—skin cancer	0.000164	0.00808	CbGpPWpGaD
Lenalidomide—Dermatitis—Vemurafenib—skin cancer	0.000163	0.000646	CcSEcCtD
Lenalidomide—Hypersensitivity—Imiquimod—skin cancer	0.000162	0.000645	CcSEcCtD
Lenalidomide—Headache—Vemurafenib—skin cancer	0.000162	0.000643	CcSEcCtD
Lenalidomide—Erythema—Temozolomide—skin cancer	0.000162	0.000642	CcSEcCtD
Lenalidomide—Malnutrition—Temozolomide—skin cancer	0.000162	0.000642	CcSEcCtD
Lenalidomide—Breast disorder—Docetaxel—skin cancer	0.000162	0.000641	CcSEcCtD
Lenalidomide—Discomfort—Bleomycin—skin cancer	0.000161	0.000641	CcSEcCtD
Lenalidomide—Malaise—Dactinomycin—skin cancer	0.000161	0.00064	CcSEcCtD
Lenalidomide—Cramp muscle—Docetaxel—skin cancer	0.000161	0.000639	CcSEcCtD
Lenalidomide—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000161	0.000639	CcSEcCtD
Lenalidomide—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000161	0.000639	CcSEcCtD
Lenalidomide—Leukopenia—Dactinomycin—skin cancer	0.00016	0.000636	CcSEcCtD
Lenalidomide—Nasopharyngitis—Docetaxel—skin cancer	0.00016	0.000634	CcSEcCtD
Lenalidomide—Dysgeusia—Temozolomide—skin cancer	0.000158	0.000629	CcSEcCtD
Lenalidomide—Asthenia—Imiquimod—skin cancer	0.000158	0.000628	CcSEcCtD
Lenalidomide—Confusional state—Bleomycin—skin cancer	0.000158	0.000627	CcSEcCtD
Lenalidomide—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000158	0.000626	CcSEcCtD
Lenalidomide—Oedema—Bleomycin—skin cancer	0.000157	0.000622	CcSEcCtD
Lenalidomide—Back pain—Temozolomide—skin cancer	0.000157	0.000621	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MC1R—skin cancer	0.000156	0.00771	CbGpPWpGaD
Lenalidomide—Pruritus—Imiquimod—skin cancer	0.000156	0.000619	CcSEcCtD
Lenalidomide—Infection—Bleomycin—skin cancer	0.000156	0.000617	CcSEcCtD
Lenalidomide—Dysphagia—Docetaxel—skin cancer	0.000154	0.000613	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—GLI1—skin cancer	0.000154	0.0076	CbGpPWpGaD
Lenalidomide—Nausea—Vemurafenib—skin cancer	0.000154	0.000609	CcSEcCtD
Lenalidomide—Thrombocytopenia—Bleomycin—skin cancer	0.000153	0.000609	CcSEcCtD
Lenalidomide—Arrhythmia—Fluorouracil—skin cancer	0.000153	0.000607	CcSEcCtD
Lenalidomide—Vision blurred—Temozolomide—skin cancer	0.000153	0.000605	CcSEcCtD
Lenalidomide—Myalgia—Dactinomycin—skin cancer	0.000152	0.000605	CcSEcCtD
Lenalidomide—Tremor—Temozolomide—skin cancer	0.000152	0.000602	CcSEcCtD
Lenalidomide—Alopecia—Fluorouracil—skin cancer	0.000151	0.000601	CcSEcCtD
Lenalidomide—Diarrhoea—Imiquimod—skin cancer	0.000151	0.000599	CcSEcCtD
Lenalidomide—Discomfort—Dactinomycin—skin cancer	0.000151	0.000597	CcSEcCtD
Lenalidomide—Angina pectoris—Docetaxel—skin cancer	0.00015	0.000597	CcSEcCtD
Lenalidomide—Ill-defined disorder—Temozolomide—skin cancer	0.00015	0.000596	CcSEcCtD
Lenalidomide—Anaemia—Temozolomide—skin cancer	0.00015	0.000594	CcSEcCtD
Lenalidomide—Anorexia—Bleomycin—skin cancer	0.000149	0.000592	CcSEcCtD
Lenalidomide—ABCB1—lymph node—skin cancer	0.000149	0.000995	CbGeAlD
Lenalidomide—Erythema—Fluorouracil—skin cancer	0.000149	0.000592	CcSEcCtD
Lenalidomide—Agitation—Temozolomide—skin cancer	0.000149	0.00059	CcSEcCtD
Lenalidomide—Angioedema—Temozolomide—skin cancer	0.000148	0.000587	CcSEcCtD
Lenalidomide—Pancytopenia—Docetaxel—skin cancer	0.000147	0.000582	CcSEcCtD
Lenalidomide—Hypotension—Bleomycin—skin cancer	0.000146	0.000581	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—SUFU—skin cancer	0.000146	0.00721	CbGpPWpGaD
Lenalidomide—Oedema—Dactinomycin—skin cancer	0.000146	0.00058	CcSEcCtD
Lenalidomide—Malaise—Temozolomide—skin cancer	0.000146	0.000579	CcSEcCtD
Lenalidomide—Dizziness—Imiquimod—skin cancer	0.000146	0.000579	CcSEcCtD
Lenalidomide—Vertigo—Temozolomide—skin cancer	0.000145	0.000577	CcSEcCtD
Lenalidomide—Infection—Dactinomycin—skin cancer	0.000145	0.000576	CcSEcCtD
Lenalidomide—Leukopenia—Temozolomide—skin cancer	0.000145	0.000575	CcSEcCtD
Lenalidomide—Neutropenia—Docetaxel—skin cancer	0.000144	0.000573	CcSEcCtD
Lenalidomide—Palpitations—Temozolomide—skin cancer	0.000143	0.000568	CcSEcCtD
Lenalidomide—Thrombocytopenia—Dactinomycin—skin cancer	0.000143	0.000568	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000143	0.000566	CcSEcCtD
Lenalidomide—Cough—Temozolomide—skin cancer	0.000141	0.000561	CcSEcCtD
Lenalidomide—Paraesthesia—Bleomycin—skin cancer	0.000141	0.000558	CcSEcCtD
Lenalidomide—Weight increased—Docetaxel—skin cancer	0.000141	0.000558	CcSEcCtD
Lenalidomide—Vision blurred—Fluorouracil—skin cancer	0.000141	0.000558	CcSEcCtD
Lenalidomide—Vomiting—Imiquimod—skin cancer	0.00014	0.000556	CcSEcCtD
Lenalidomide—Weight decreased—Docetaxel—skin cancer	0.00014	0.000555	CcSEcCtD
Lenalidomide—Hypertension—Temozolomide—skin cancer	0.00014	0.000555	CcSEcCtD
Lenalidomide—Dyspnoea—Bleomycin—skin cancer	0.00014	0.000554	CcSEcCtD
Lenalidomide—Anorexia—Dactinomycin—skin cancer	0.000139	0.000553	CcSEcCtD
Lenalidomide—Rash—Imiquimod—skin cancer	0.000139	0.000552	CcSEcCtD
Lenalidomide—Dermatitis—Imiquimod—skin cancer	0.000139	0.000551	CcSEcCtD
Lenalidomide—Pneumonia—Docetaxel—skin cancer	0.000139	0.00055	CcSEcCtD
Lenalidomide—Headache—Imiquimod—skin cancer	0.000138	0.000548	CcSEcCtD
Lenalidomide—Anaemia—Fluorouracil—skin cancer	0.000138	0.000547	CcSEcCtD
Lenalidomide—Arthralgia—Temozolomide—skin cancer	0.000138	0.000547	CcSEcCtD
Lenalidomide—Myalgia—Temozolomide—skin cancer	0.000138	0.000547	CcSEcCtD
Lenalidomide—Infestation NOS—Docetaxel—skin cancer	0.000138	0.000547	CcSEcCtD
Lenalidomide—Infestation—Docetaxel—skin cancer	0.000138	0.000547	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—skin cancer	0.000138	0.00679	CbGpPWpGaD
Lenalidomide—Anxiety—Temozolomide—skin cancer	0.000137	0.000545	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000137	0.000543	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000137	0.000542	CcSEcCtD
Lenalidomide—Discomfort—Temozolomide—skin cancer	0.000136	0.00054	CcSEcCtD
Lenalidomide—Decreased appetite—Bleomycin—skin cancer	0.000136	0.00054	CcSEcCtD
Lenalidomide—Acute coronary syndrome—Docetaxel—skin cancer	0.000136	0.000539	CcSEcCtD
Lenalidomide—Renal failure—Docetaxel—skin cancer	0.000135	0.000537	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Docetaxel—skin cancer	0.000135	0.000536	CcSEcCtD
Lenalidomide—Myocardial infarction—Docetaxel—skin cancer	0.000135	0.000536	CcSEcCtD
Lenalidomide—Dry mouth—Temozolomide—skin cancer	0.000135	0.000535	CcSEcCtD
Lenalidomide—Stomatitis—Docetaxel—skin cancer	0.000134	0.000533	CcSEcCtD
Lenalidomide—Pain—Bleomycin—skin cancer	0.000134	0.000531	CcSEcCtD
Lenalidomide—Conjunctivitis—Docetaxel—skin cancer	0.000134	0.000531	CcSEcCtD
Lenalidomide—Leukopenia—Fluorouracil—skin cancer	0.000133	0.00053	CcSEcCtD
Lenalidomide—Confusional state—Temozolomide—skin cancer	0.000133	0.000529	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000133	0.000528	CcSEcCtD
Lenalidomide—Oedema—Temozolomide—skin cancer	0.000132	0.000524	CcSEcCtD
Lenalidomide—Infection—Temozolomide—skin cancer	0.000131	0.000521	CcSEcCtD
Lenalidomide—Nausea—Imiquimod—skin cancer	0.000131	0.00052	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Docetaxel—skin cancer	0.00013	0.000517	CcSEcCtD
Lenalidomide—Epistaxis—Docetaxel—skin cancer	0.00013	0.000516	CcSEcCtD
Lenalidomide—Nervous system disorder—Temozolomide—skin cancer	0.00013	0.000514	CcSEcCtD
Lenalidomide—Thrombocytopenia—Temozolomide—skin cancer	0.000129	0.000513	CcSEcCtD
Lenalidomide—Feeling abnormal—Bleomycin—skin cancer	0.000129	0.000512	CcSEcCtD
Lenalidomide—Agranulocytosis—Docetaxel—skin cancer	0.000129	0.00051	CcSEcCtD
Lenalidomide—Skin disorder—Temozolomide—skin cancer	0.000128	0.000509	CcSEcCtD
Lenalidomide—Hyperhidrosis—Temozolomide—skin cancer	0.000128	0.000507	CcSEcCtD
Lenalidomide—Chest pain—Fluorouracil—skin cancer	0.000127	0.000504	CcSEcCtD
Lenalidomide—Myalgia—Fluorouracil—skin cancer	0.000127	0.000504	CcSEcCtD
Lenalidomide—Decreased appetite—Dactinomycin—skin cancer	0.000127	0.000504	CcSEcCtD
Lenalidomide—Fatigue—Dactinomycin—skin cancer	0.000126	0.0005	CcSEcCtD
Lenalidomide—Anorexia—Temozolomide—skin cancer	0.000126	0.0005	CcSEcCtD
Lenalidomide—Discomfort—Fluorouracil—skin cancer	0.000125	0.000498	CcSEcCtD
Lenalidomide—Pain—Dactinomycin—skin cancer	0.000125	0.000496	CcSEcCtD
Lenalidomide—Urticaria—Bleomycin—skin cancer	0.000124	0.000494	CcSEcCtD
Lenalidomide—Haemoglobin—Docetaxel—skin cancer	0.000124	0.000493	CcSEcCtD
Lenalidomide—Rhinitis—Docetaxel—skin cancer	0.000124	0.000492	CcSEcCtD
Lenalidomide—Body temperature increased—Bleomycin—skin cancer	0.000124	0.000491	CcSEcCtD
Lenalidomide—Haemorrhage—Docetaxel—skin cancer	0.000124	0.000491	CcSEcCtD
Lenalidomide—Hepatitis—Docetaxel—skin cancer	0.000124	0.000491	CcSEcCtD
Lenalidomide—Hypoaesthesia—Docetaxel—skin cancer	0.000123	0.000488	CcSEcCtD
Lenalidomide—Confusional state—Fluorouracil—skin cancer	0.000123	0.000487	CcSEcCtD
Lenalidomide—Pharyngitis—Docetaxel—skin cancer	0.000123	0.000487	CcSEcCtD
Lenalidomide—Urinary tract disorder—Docetaxel—skin cancer	0.000122	0.000485	CcSEcCtD
Lenalidomide—Oedema peripheral—Docetaxel—skin cancer	0.000122	0.000483	CcSEcCtD
Lenalidomide—Oedema—Fluorouracil—skin cancer	0.000122	0.000483	CcSEcCtD
Lenalidomide—Connective tissue disorder—Docetaxel—skin cancer	0.000121	0.000482	CcSEcCtD
Lenalidomide—Urethral disorder—Docetaxel—skin cancer	0.000121	0.000481	CcSEcCtD
Lenalidomide—Infection—Fluorouracil—skin cancer	0.000121	0.00048	CcSEcCtD
Lenalidomide—Feeling abnormal—Dactinomycin—skin cancer	0.00012	0.000478	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00012	0.000478	CcSEcCtD
Lenalidomide—Insomnia—Temozolomide—skin cancer	0.000119	0.000474	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Dactinomycin—skin cancer	0.000119	0.000474	CcSEcCtD
Lenalidomide—Nervous system disorder—Fluorouracil—skin cancer	0.000119	0.000474	CcSEcCtD
Lenalidomide—Thrombocytopenia—Fluorouracil—skin cancer	0.000119	0.000473	CcSEcCtD
Lenalidomide—Visual impairment—Docetaxel—skin cancer	0.000119	0.000473	CcSEcCtD
Lenalidomide—Tachycardia—Fluorouracil—skin cancer	0.000119	0.000471	CcSEcCtD
Lenalidomide—Paraesthesia—Temozolomide—skin cancer	0.000119	0.000471	CcSEcCtD
Lenalidomide—Dyspnoea—Temozolomide—skin cancer	0.000118	0.000467	CcSEcCtD
Lenalidomide—Somnolence—Temozolomide—skin cancer	0.000117	0.000466	CcSEcCtD
Lenalidomide—Erythema multiforme—Docetaxel—skin cancer	0.000117	0.000464	CcSEcCtD
Lenalidomide—Dyspepsia—Temozolomide—skin cancer	0.000116	0.000461	CcSEcCtD
Lenalidomide—PTGS2—Overview of nanoparticle effects—IL6—skin cancer	0.000116	0.00573	CbGpPWpGaD
Lenalidomide—Anorexia—Fluorouracil—skin cancer	0.000116	0.00046	CcSEcCtD
Lenalidomide—Eye disorder—Docetaxel—skin cancer	0.000116	0.000459	CcSEcCtD
Lenalidomide—Abdominal pain—Dactinomycin—skin cancer	0.000115	0.000458	CcSEcCtD
Lenalidomide—Body temperature increased—Dactinomycin—skin cancer	0.000115	0.000458	CcSEcCtD
Lenalidomide—Hypersensitivity—Bleomycin—skin cancer	0.000115	0.000458	CcSEcCtD
Lenalidomide—Decreased appetite—Temozolomide—skin cancer	0.000115	0.000456	CcSEcCtD
Lenalidomide—Flushing—Docetaxel—skin cancer	0.000115	0.000455	CcSEcCtD
Lenalidomide—Cardiac disorder—Docetaxel—skin cancer	0.000115	0.000455	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Temozolomide—skin cancer	0.000114	0.000453	CcSEcCtD
Lenalidomide—Fatigue—Temozolomide—skin cancer	0.000114	0.000452	CcSEcCtD
Lenalidomide—Hypotension—Fluorouracil—skin cancer	0.000114	0.000451	CcSEcCtD
Lenalidomide—Constipation—Temozolomide—skin cancer	0.000113	0.000448	CcSEcCtD
Lenalidomide—Pain—Temozolomide—skin cancer	0.000113	0.000448	CcSEcCtD
Lenalidomide—Asthenia—Bleomycin—skin cancer	0.000112	0.000446	CcSEcCtD
Lenalidomide—Angiopathy—Docetaxel—skin cancer	0.000112	0.000445	CcSEcCtD
Lenalidomide—Immune system disorder—Docetaxel—skin cancer	0.000112	0.000443	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—SHH—skin cancer	0.000111	0.0055	CbGpPWpGaD
Lenalidomide—Mediastinal disorder—Docetaxel—skin cancer	0.000111	0.000442	CcSEcCtD
Lenalidomide—Chills—Docetaxel—skin cancer	0.000111	0.00044	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000111	0.00044	CcSEcCtD
Lenalidomide—Pruritus—Bleomycin—skin cancer	0.000111	0.00044	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—RASA1—skin cancer	0.000111	0.00546	CbGpPWpGaD
Lenalidomide—Arrhythmia—Docetaxel—skin cancer	0.00011	0.000438	CcSEcCtD
Lenalidomide—Insomnia—Fluorouracil—skin cancer	0.00011	0.000437	CcSEcCtD
Lenalidomide—Paraesthesia—Fluorouracil—skin cancer	0.000109	0.000434	CcSEcCtD
Lenalidomide—Alopecia—Docetaxel—skin cancer	0.000109	0.000434	CcSEcCtD
Lenalidomide—Feeling abnormal—Temozolomide—skin cancer	0.000109	0.000432	CcSEcCtD
Lenalidomide—Dyspnoea—Fluorouracil—skin cancer	0.000109	0.000431	CcSEcCtD
Lenalidomide—Mental disorder—Docetaxel—skin cancer	0.000108	0.00043	CcSEcCtD
Lenalidomide—Somnolence—Fluorouracil—skin cancer	0.000108	0.000429	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Temozolomide—skin cancer	0.000108	0.000429	CcSEcCtD
Lenalidomide—Erythema—Docetaxel—skin cancer	0.000108	0.000427	CcSEcCtD
Lenalidomide—Malnutrition—Docetaxel—skin cancer	0.000108	0.000427	CcSEcCtD
Lenalidomide—Hypersensitivity—Dactinomycin—skin cancer	0.000108	0.000427	CcSEcCtD
Lenalidomide—Dyspepsia—Fluorouracil—skin cancer	0.000107	0.000425	CcSEcCtD
Lenalidomide—Decreased appetite—Fluorouracil—skin cancer	0.000106	0.00042	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—SMO—skin cancer	0.000106	0.00521	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTCH1—skin cancer	0.000106	0.00521	CbGpPWpGaD
Lenalidomide—Dysgeusia—Docetaxel—skin cancer	0.000105	0.000418	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000105	0.000417	CcSEcCtD
Lenalidomide—Urticaria—Temozolomide—skin cancer	0.000105	0.000416	CcSEcCtD
Lenalidomide—Asthenia—Dactinomycin—skin cancer	0.000105	0.000416	CcSEcCtD
Lenalidomide—Abdominal pain—Temozolomide—skin cancer	0.000104	0.000414	CcSEcCtD
Lenalidomide—Body temperature increased—Temozolomide—skin cancer	0.000104	0.000414	CcSEcCtD
Lenalidomide—Back pain—Docetaxel—skin cancer	0.000104	0.000413	CcSEcCtD
Lenalidomide—Pain—Fluorouracil—skin cancer	0.000104	0.000413	CcSEcCtD
Lenalidomide—Muscle spasms—Docetaxel—skin cancer	0.000103	0.000411	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PTGER4—skin cancer	0.000103	0.00507	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Fluorouracil—skin cancer	0.0001	0.000398	CcSEcCtD
Lenalidomide—Diarrhoea—Dactinomycin—skin cancer	9.99e-05	0.000397	CcSEcCtD
Lenalidomide—Vomiting—Bleomycin—skin cancer	9.96e-05	0.000395	CcSEcCtD
Lenalidomide—Anaemia—Docetaxel—skin cancer	9.95e-05	0.000395	CcSEcCtD
Lenalidomide—Rash—Bleomycin—skin cancer	9.87e-05	0.000392	CcSEcCtD
Lenalidomide—Dermatitis—Bleomycin—skin cancer	9.86e-05	0.000392	CcSEcCtD
Lenalidomide—Hypersensitivity—Temozolomide—skin cancer	9.73e-05	0.000386	CcSEcCtD
Lenalidomide—Urticaria—Fluorouracil—skin cancer	9.67e-05	0.000384	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	9.67e-05	0.00477	CbGpPWpGaD
Lenalidomide—Syncope—Docetaxel—skin cancer	9.65e-05	0.000383	CcSEcCtD
Lenalidomide—Leukopenia—Docetaxel—skin cancer	9.63e-05	0.000382	CcSEcCtD
Lenalidomide—Body temperature increased—Fluorouracil—skin cancer	9.62e-05	0.000382	CcSEcCtD
Lenalidomide—Palpitations—Docetaxel—skin cancer	9.51e-05	0.000378	CcSEcCtD
Lenalidomide—Asthenia—Temozolomide—skin cancer	9.48e-05	0.000376	CcSEcCtD
Lenalidomide—Loss of consciousness—Docetaxel—skin cancer	9.46e-05	0.000375	CcSEcCtD
Lenalidomide—Cough—Docetaxel—skin cancer	9.39e-05	0.000373	CcSEcCtD
Lenalidomide—Pruritus—Temozolomide—skin cancer	9.35e-05	0.000371	CcSEcCtD
Lenalidomide—Nausea—Bleomycin—skin cancer	9.3e-05	0.000369	CcSEcCtD
Lenalidomide—Hypertension—Docetaxel—skin cancer	9.29e-05	0.000369	CcSEcCtD
Lenalidomide—Vomiting—Dactinomycin—skin cancer	9.29e-05	0.000369	CcSEcCtD
Lenalidomide—Rash—Dactinomycin—skin cancer	9.21e-05	0.000365	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	9.16e-05	0.00452	CbGpPWpGaD
Lenalidomide—Chest pain—Docetaxel—skin cancer	9.16e-05	0.000364	CcSEcCtD
Lenalidomide—Arthralgia—Docetaxel—skin cancer	9.16e-05	0.000364	CcSEcCtD
Lenalidomide—Myalgia—Docetaxel—skin cancer	9.16e-05	0.000364	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	9.1e-05	0.000361	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—FOXO4—skin cancer	9.08e-05	0.00448	CbGpPWpGaD
Lenalidomide—Diarrhoea—Temozolomide—skin cancer	9.04e-05	0.000359	CcSEcCtD
Lenalidomide—Hypersensitivity—Fluorouracil—skin cancer	8.97e-05	0.000356	CcSEcCtD
Lenalidomide—Dry mouth—Docetaxel—skin cancer	8.96e-05	0.000356	CcSEcCtD
Lenalidomide—Confusional state—Docetaxel—skin cancer	8.86e-05	0.000352	CcSEcCtD
Lenalidomide—Oedema—Docetaxel—skin cancer	8.78e-05	0.000349	CcSEcCtD
Lenalidomide—Dizziness—Temozolomide—skin cancer	8.73e-05	0.000347	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	8.73e-05	0.00431	CbGpPWpGaD
Lenalidomide—Infection—Docetaxel—skin cancer	8.73e-05	0.000346	CcSEcCtD
Lenalidomide—Nausea—Dactinomycin—skin cancer	8.67e-05	0.000344	CcSEcCtD
Lenalidomide—Shock—Docetaxel—skin cancer	8.64e-05	0.000343	CcSEcCtD
Lenalidomide—Nervous system disorder—Docetaxel—skin cancer	8.61e-05	0.000342	CcSEcCtD
Lenalidomide—Pruritus—Fluorouracil—skin cancer	8.61e-05	0.000342	CcSEcCtD
Lenalidomide—Thrombocytopenia—Docetaxel—skin cancer	8.6e-05	0.000341	CcSEcCtD
Lenalidomide—Tachycardia—Docetaxel—skin cancer	8.57e-05	0.00034	CcSEcCtD
Lenalidomide—Skin disorder—Docetaxel—skin cancer	8.53e-05	0.000339	CcSEcCtD
Lenalidomide—Vomiting—Temozolomide—skin cancer	8.4e-05	0.000333	CcSEcCtD
Lenalidomide—Anorexia—Docetaxel—skin cancer	8.37e-05	0.000332	CcSEcCtD
Lenalidomide—Rash—Temozolomide—skin cancer	8.33e-05	0.000331	CcSEcCtD
Lenalidomide—Diarrhoea—Fluorouracil—skin cancer	8.33e-05	0.000331	CcSEcCtD
Lenalidomide—Dermatitis—Temozolomide—skin cancer	8.32e-05	0.00033	CcSEcCtD
Lenalidomide—Headache—Temozolomide—skin cancer	8.27e-05	0.000328	CcSEcCtD
Lenalidomide—Hypotension—Docetaxel—skin cancer	8.21e-05	0.000326	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	8.18e-05	0.00404	CbGpPWpGaD
Lenalidomide—Dizziness—Fluorouracil—skin cancer	8.05e-05	0.000319	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Docetaxel—skin cancer	8e-05	0.000318	CcSEcCtD
Lenalidomide—Insomnia—Docetaxel—skin cancer	7.94e-05	0.000315	CcSEcCtD
Lenalidomide—Paraesthesia—Docetaxel—skin cancer	7.89e-05	0.000313	CcSEcCtD
Lenalidomide—Nausea—Temozolomide—skin cancer	7.85e-05	0.000311	CcSEcCtD
Lenalidomide—Dyspnoea—Docetaxel—skin cancer	7.83e-05	0.000311	CcSEcCtD
Lenalidomide—Somnolence—Docetaxel—skin cancer	7.81e-05	0.00031	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—skin cancer	7.79e-05	0.00384	CbGpPWpGaD
Lenalidomide—Vomiting—Fluorouracil—skin cancer	7.74e-05	0.000307	CcSEcCtD
Lenalidomide—Dyspepsia—Docetaxel—skin cancer	7.73e-05	0.000307	CcSEcCtD
Lenalidomide—Rash—Fluorouracil—skin cancer	7.67e-05	0.000305	CcSEcCtD
Lenalidomide—Dermatitis—Fluorouracil—skin cancer	7.67e-05	0.000304	CcSEcCtD
Lenalidomide—Decreased appetite—Docetaxel—skin cancer	7.64e-05	0.000303	CcSEcCtD
Lenalidomide—Headache—Fluorouracil—skin cancer	7.62e-05	0.000303	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Docetaxel—skin cancer	7.58e-05	0.000301	CcSEcCtD
Lenalidomide—Fatigue—Docetaxel—skin cancer	7.57e-05	0.000301	CcSEcCtD
Lenalidomide—Constipation—Docetaxel—skin cancer	7.51e-05	0.000298	CcSEcCtD
Lenalidomide—Pain—Docetaxel—skin cancer	7.51e-05	0.000298	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	7.37e-05	0.00363	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Docetaxel—skin cancer	7.24e-05	0.000287	CcSEcCtD
Lenalidomide—Nausea—Fluorouracil—skin cancer	7.23e-05	0.000287	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Docetaxel—skin cancer	7.18e-05	0.000285	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	7.04e-05	0.00347	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—skin cancer	6.95e-05	0.00343	CbGpPWpGaD
Lenalidomide—Body temperature increased—Docetaxel—skin cancer	6.94e-05	0.000276	CcSEcCtD
Lenalidomide—Abdominal pain—Docetaxel—skin cancer	6.94e-05	0.000276	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CDK4—skin cancer	6.93e-05	0.00342	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	6.85e-05	0.00338	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	6.5e-05	0.0032	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Docetaxel—skin cancer	6.47e-05	0.000257	CcSEcCtD
Lenalidomide—Asthenia—Docetaxel—skin cancer	6.3e-05	0.00025	CcSEcCtD
Lenalidomide—Pruritus—Docetaxel—skin cancer	6.21e-05	0.000247	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TERT—skin cancer	6.07e-05	0.00299	CbGpPWpGaD
Lenalidomide—Diarrhoea—Docetaxel—skin cancer	6.01e-05	0.000239	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	5.99e-05	0.00295	CbGpPWpGaD
Lenalidomide—Dizziness—Docetaxel—skin cancer	5.81e-05	0.000231	CcSEcCtD
Lenalidomide—Vomiting—Docetaxel—skin cancer	5.59e-05	0.000222	CcSEcCtD
Lenalidomide—Rash—Docetaxel—skin cancer	5.54e-05	0.00022	CcSEcCtD
Lenalidomide—Dermatitis—Docetaxel—skin cancer	5.53e-05	0.00022	CcSEcCtD
Lenalidomide—Headache—Docetaxel—skin cancer	5.5e-05	0.000218	CcSEcCtD
Lenalidomide—Nausea—Docetaxel—skin cancer	5.22e-05	0.000207	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—NRAS—skin cancer	5.05e-05	0.00249	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—BRAF—skin cancer	4.81e-05	0.00237	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	4.71e-05	0.00232	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	4.71e-05	0.00232	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—KRAS—skin cancer	4.35e-05	0.00215	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—skin cancer	3.7e-05	0.00182	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—skin cancer	3.41e-05	0.00168	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	3.34e-05	0.00165	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLIN2—skin cancer	3.28e-05	0.00162	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CSPG4—skin cancer	3.16e-05	0.00156	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NRAS—skin cancer	3.02e-05	0.00149	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—skin cancer	2.95e-05	0.00145	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—skin cancer	2.7e-05	0.00133	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CSPG4—skin cancer	2.64e-05	0.0013	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KRAS—skin cancer	2.6e-05	0.00128	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	2.39e-05	0.00118	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLIN2—skin cancer	2.33e-05	0.00115	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—skin cancer	2.31e-05	0.00114	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.25e-05	0.00111	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HRAS—skin cancer	2.21e-05	0.00109	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ENO2—skin cancer	2.15e-05	0.00106	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SHH—skin cancer	2.15e-05	0.00106	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—skin cancer	2.11e-05	0.00104	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2e-05	0.000988	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CSPG4—skin cancer	1.87e-05	0.000925	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ENO2—skin cancer	1.8e-05	0.000887	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FOXO4—skin cancer	1.75e-05	0.000863	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.6e-05	0.000788	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.42e-05	0.000701	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ENO2—skin cancer	1.27e-05	0.000628	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERCC2—skin cancer	1.25e-05	0.000615	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TERT—skin cancer	1.17e-05	0.000576	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ERCC2—skin cancer	1.04e-05	0.000515	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BRAF—skin cancer	9.26e-06	0.000456	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ERCC2—skin cancer	7.4e-06	0.000365	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRAS—skin cancer	5.82e-06	0.000287	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—skin cancer	5.01e-06	0.000247	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—skin cancer	4.44e-06	0.000219	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—skin cancer	4.26e-06	0.00021	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—skin cancer	4.07e-06	0.000201	CbGpPWpGaD
